Clerkenwell Health is proud to announce the launch of its foundation course for Psychedelic-Assisted Therapy, a comprehensive 30-hour program that brings together leading experts in the field.
Owlstone Medical, a global leader in Breath Biopsy for early disease detection and precision medicine, has announced a funding to the tune of $6.5 million.
In the heart of Montreal sits the non-profit organization Centech, a place that supports projects and startups with high growth potential – from conception right through to commercialization, which it says is thanks to a bold, collaborative, and passionate...
Response Pharmaceuticals, Inc., has unveiled significant findings from its Phase 1b clinical trial of RDX-002, signaling a potential breakthrough in combatting antipsychotic-induced weight gain (AIWG).
Wuxi AppTec says recent allegations made by the US government that it has shared clients' data with Beijing without consent are ‘misleading’ and ‘inaccurate’.
Today (April 24), Astellas Pharma Inc. revealed that XTANDITM (enzalutamide) has received a label extension from the European Commission, marking it as the inaugural and only novel hormone therapy endorsed for high-risk biochemical recurrent non-metastatic...
In a remarkable development, Front Line Medical Technologies Inc., an innovator in trauma care medical devices, has announced the attainment of CE marking for its COBRA-OS (Control of Bleeding, Resuscitation, Arterial Occlusion System).
Oncimmune Holdings plc, a prominent autoantibody profiling company catering to the pharmaceutical and biotechnology sectors, is expanding its horizons by delving into the realm of biomarkers for age-related diseases.
At CPhI North America, Quotient Sciences is looking forward to reconnecting with its customers and giving them a preview of how we are looking to expand Translational Pharmaceutics further within the US.
After two major acquisitions, Biosynth is coming to CPHI North America ready to tell the industry about its enhanced capabilities and connect with new and existing customers.
Torbay Pharmaceuticals is a sterile injectable contract manufacturer and licence holder based in Devon, UK. We spoke with CEO Emma Rooth about the company's heritage and how it is striving to support the U.S. market.
Ahead of CPHI North America, we caught up with Lisa Stiles, director, business development at Selkirk Pharma, an exhibitor at the event, to find out how the CMO is navigating regulatory changes, challenges and more.
LGM Pharma is a leading CDMO provider of comprehensive API sourcing and drug product contract development and manufacturing solutions to the pharmaceutical, biotechnology, and compounding pharmacy industries.
Earlier this week, Charles River Laboratories International, Inc. revealed its Alternative Methods Advancement Project (AMAP), which it said is a strong initiative aimed at changing drug discovery and development by exploring alternatives to animal testing.
To make testing for colorectal cancer more bearable than biannunal colonoscopies, a test has been designed that is simple, effective, non-invasive and not unpleasant.
Yesterday, Thermo Fisher Scientific opened its first Innovation Lab in Center Valley, Pennsylvania., as a space where partners can come together to collaborate, innovate, and ideate on solutions to the biggest clinical supply chain pain points.
During DCAT this year, CEO Gaston Salinas from Botanical Solution Inc., (BSI), sat down with Liza Laws, the senior editor of OSP and BPR to discuss his company’s pioneering work in revolutionizing vaccine adjuvant production.
Pharma companies need to take greater ownership to make sure data quality and governance is accomplished - and it is important to keep in mind the ethics of AI use will remain front and centre for the pharma industry.
Bios Health Group, a leading strategic and investment partner for life science companies and investors, has officially introduced the Bios Innovation Circle.
In a recent discussion with Jan Vertommen, vice president and head of commercial development for the small molecules division at Lonza, key insights were shared regarding the pharmaceutical industry's current landscape and future trajectory.
Within the rapidly evolving landscape of decentralized clinical trials (DCTs), one critical challenge persists: the accurate monitoring of cough symptoms.
Michael Fronstin, global head of client partnership and commercialization at the company said the combination of Oracle’s life sciences expertise and platform technology help CROs win more business and run trials more efficiently.
AstraZeneca's latest modelling analysis, IMPACT CKD, presented at the 2024 ISN World Congress of Nephrology (WCN'24) in Buenos Aires, paints a concerning picture of the future of chronic kidney disease (CKD) across eight countries.
Bio Pharma Reporter and Outsourcing Pharma is back with our latest instalment of movers and shakers - breaking down all the key pharma industry appointments that you should know about. KBI Biopharma, Veranova and Kindeva Drug Delivery are among the companies...
Elisa Cascade is the chief product officer at Advarra and is responsible for driving the clinical research company's technology product vision and management. We had a fascinating and inspiring conversation with her - touching on imposter syndrome,...
Andaman7, a free healthcare app aiming to revolutionize patient engagement and streamline communication between patients and researchers, has unveiled its latest update, Andaman7 version 5, featuring advanced artificial intelligence (AI) capabilities.
GSK's Jemperli (dostarlimab) has been approved for use within NHS Scotland, marking a significant step in the treatment of eligible endometrial cancer patients in the region.
In an overwhelming response to the news that SimBioSys and General Inception had joined forces to use advanced AI and biophysical modeling, to gain deeper insights into tumor biology, the industry has spoken.
Molecure S.A., a leading biotechnology company focused on drug discovery and development, has unveiled its annual report for 2023 at the start of the new financial year.
Precision oncology innovator SimBioSys and General Inception have joined forces in a strategic partnership aimed at revolutionizing cancer drug development.
Bora Pharmaceuticals Co., Ltd. yesterday (April 1) finalized the acquisition of Upsher-Smith Laboratories, Inc., a leading generics manufacturer based in Minnesota, U.S., from its previous owners, Sawai Group Holdings and Sumitomo Corporation of Americas.
In an important announcement today (April 2), Hutchmed and Innovent jointly revealed the acceptance of their New Drug Application (NDA) in China for the combination of Fruquintinib with Sintilimab.
OSP was lucky enough to talk to David Menzies (pictured), executive director, technology solutions at ICON to find out how he thinks the pharma industry needs to overcome the real-world data challenges.
In an exciting collaboration, modern mental health company, Clerkenwell Health, and Beckley Psytech, a clinical-stage biotechnology company, have launched a phase 2a study aimed at investigating a potential breakthrough treatment for alcohol use disorder...
In order to find out, OSP sat down with Brigham Hyde to ask him a number of questions about the company's technology and what it is doing to upgrade traditional trial methods.
Today (March 26) One2Treat, a progressive startup specializing in digital health solutions, has launched a forward-thinking approach aimed at tackling key challenges in the biopharma industry.
Medtech startup Metyos has secured €2.3 million in pre-seed funding to advance its mission of improving the lives of chronic kidney disease (CKD) patients worldwide.
Under the agreement, Closed Loop Medicine – a leading TechBio company – and pharmaceutical company, Teva UK, will investigate opportunities to use Closed Loop Medicine’s proprietary software as a medical device (SaMD) technology platform.
AstraZeneca recently announced its £650 million investment in the UK, held up by Chancellor Jeremy Hunt as a ‘vote of confidence’ in the country’s life sciences sector.
With the pharma and healthcare landscape increasingly being shaped by artificial intelligence (AI), the US Food and Drug Administration (FDA) has taken proactive steps to outline a comprehensive strategy for regulating AI in medical products.
